

**DR. REDDY'S LABORATORIES LTD.**  
8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500034. Telangana, India.

## CONTACT

INVESTOR RELATIONS	MEDIA RELATIONS
AISHWARYA SITHARAM <a href="mailto:AISHWARYASITHARAM@DRREDDYS.COM">AISHWARYASITHARAM@DRREDDYS.COM</a>	PRIYA K <a href="mailto:PRIYAK@DRREDDYS.COM">PRIYAK@DRREDDYS.COM</a>

## Dr. Reddy's launches Hevaxin®, a novel recombinant Hepatitis E vaccine in India

**Hyderabad India; January 06, 2026**— Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Hevaxin®, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India.

Hevaxin® is the only vaccine approved by the Drug Controller General of India (DCGI) for the indication of active immunization against HEV infection in adults aged 18 to 65 years in India. The clinical studies have demonstrated that Hevaxin® provides protection, supports long-lasting immunity, and has shown a favourable immune response with an established safety and tolerability profile<sup>1</sup>.

According to WHO, Hepatitis E infects about 20 million people every year, causing 3.4 million illnesses, 70,000 deaths, and 3,000 stillbirths worldwide<sup>2</sup>. In India, it is a major health problem, responsible for up to 40% of acute hepatitis cases and 15–45% of acute liver failure cases<sup>3</sup>. People most at risk for Hepatitis E include women of childbearing age group, chronic liver disease patients, people with weak immunity, and patients preparing for organ transplantation<sup>4</sup>. Studies also show Hepatitis E often triggers severe liver failure, with death rates reaching up to 67%<sup>5</sup>. The WHO has approved Hepatitis E vaccine as the fifth vaccine under the International Coordinating Group (ICG) mechanism<sup>6</sup>.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's, said: "The launch of Hevaxin® is a significant step in reinforcing our commitment to preventive healthcare and advancing our vaccine portfolio. Hepatitis E remains a serious threat to patients with chronic liver disease, often leading to acute-on-chronic liver failure and high fatality rates. With this introduction, we aim to provide a first-in-class preventive option, addressing a critical unmet patient need. The vaccine also supports the National Viral Hepatitis Control Programme, under the Ministry of Health and Family Welfare, aimed at reducing the morbidity and mortality associated with Hepatitis E in India."

<sup>1</sup> Zhu FC, et al. Lancet. 2010; 376(9744):895–902.

<sup>2</sup> WHO position paper on hepatitis E vaccines - May 2015 ISBN: ISSN 0049-8114

<sup>3</sup> National Centre for Disease Control (NCDC). (2024). Viral Hepatitis- The Silent Disease

Facts and Treatment Guidelines. Retrieved from [https://ncdc.mohfw.gov.in/wpcontent/uploads/2024/04/guideline\\_hep20158117187417.pdf](https://ncdc.mohfw.gov.in/wpcontent/uploads/2024/04/guideline_hep20158117187417.pdf)

<sup>4</sup> Global vaccination against hepatitis E virus: position paper from the European Society of Clinical Microbiology and Infectious Diseases Viral Hepatitis Study Group. Clin Microbiol Infect. 2025 Feb;31(2):201-210. doi:10.1016/j.cmi.2024.11.016

<sup>5</sup> Buti M, Ruiz-Cobo JC, Esteban R, Riveiro-Barciela M. Hepatitis E as a trigger for acute-on-chronic liver failure. Clin Mol Hepatol. 2025;31(Suppl):S196-S204.

<sup>6</sup> <https://www.who.int/news-room/fact-sheets/detail/hepatitis-e>

Dr. Reddy's has partnered with Shenzhen Mellow Hope Pharm as well as Urihk Pharmaceutical for marketing and distribution of Hevaxin® in India.

---

**About Dr. Reddy's:** Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: [www.drreddys.com](http://www.drreddys.com).

---

**Disclaimer:** This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.